.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BD01_Amiodarone.Amiodarone .Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BD01_Amiodarone.Amiodarone| name: | Amiodarone |
| ATC code: | C01BD01 | route: | oral |
| n-compartments | 2 |
Amiodarone is a class III antiarrhythmic agent primarily used for the treatment and prevention of various types of cardiac arrhythmias, including ventricular tachycardia and atrial fibrillation. It is approved for use in many countries but is reserved for life-threatening arrhythmias due to potential for serious side effects.
Pharmacokinetic parameters in adult healthy individuals or cardiac patients following oral administration.
Lehnert, A, et al., & Treluyer, JM (2022). Amiodarone/N-desethylamiodarone population pharmacokinetics in paediatric patients. British journal of clinical pharmacology 88(12) 5369–5377. DOI:10.1111/bcp.15458 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35816412
Pollak, PT, et al., & Shafer, SL (2000). Population pharmacokinetics of long-term oral amiodarone therapy. Clinical pharmacology and therapeutics 67(6) 642–652. DOI:10.1067/mcp.2000.107047 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10872646
Hirai, T, et al., & Iwamoto, T (2022). Population Pharmacokinetic Model of Amiodarone and N-Desethylamiodarone Focusing on Glucocorticoid and Inflammation. Biological & pharmaceutical bulletin 45(7) 948–954. DOI:10.1248/bpb.b21-00940 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35786602